COMP <GO>
DGX vs LLY // DIVIDEND YIELD & FCF PAYOUT SAFETY
Quest Diagnostics Incorporated (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: DGX 5
— LLY 10
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: DGX
LAST: $251.82 (-0.43%) • MKT CAP: $27.83B
dividend-safety
1.27%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
dividend-safety
0.49%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DGX VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DGX | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 33.20% | 83.64% | -50.44 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 10.30% | 32.36% | -22.06 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 16.3x | 36.4x | -20.12 | DGX | /valuation <GO> |
| Free Cash Flow Yield | 4.88% | 2.30% | +2.58 | DGX | /fcf-yield <GO> |
| Operating Margin | 14.10% | 40.21% | -26.11 | LLY | /operating-margins <GO> |
| Net Profit Margin | 9.00% | 31.90% | -22.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 11.80% | 45.51% | -33.71 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 1.27% | 0.49% | +0.78 | DGX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.01 | 9.29 | -5.28 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.77% | +0.13 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 68.3 | 77.9 | -9.55 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 0.51 | +0.50 | DGX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.1x | 26.3x | -0.15 | DGX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $27.83B | $1.33T | -$1.31T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DGX REV | LLY REV | DGX GROSS % | LLY GROSS % | DGX FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $11.04B | $65.18B | 33.2% | 83.0% | $1.36B | $16.81B |
| FY 2024 | $9.87B | $45.04B | 32.9% | 81.3% | $909.0M | $8.82B |
| FY 2023 | $9.25B | $34.12B | 44.0% | 79.3% | $855.7M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DGX // BETA 1.01
LLY // BETA 0.51